Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial
Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.

Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new revision v3.4.2 was added to the study record history, replacing the previous v3.4.1. This update is a metadata-level change and does not alter substantive study data or results.SummaryDifference0.1%

- Check20 days agoChange DetectedThe record history now shows a new revision v3.4.1 added and the previous v3.4.0 removed, reflecting a minor update to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedThe updates are limited to user interface elements (Show glossary, color-coded diffs) and metadata (revision labels), with the No FEAR Act data item removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check42 days agoChange DetectedRevision history updated: added v3.3.4 and removed v3.3.3. This update affects only the page's revision log and not substantive study data.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a new revision entry (Revision: v3.3.3) to the Record History and removed the previous Revision: v3.3.2 along with the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check92 days agoChange DetectedThe page footer now displays Revision: v3.3.2, replacing the previous Revision: v3.2.0.SummaryDifference0.1%

Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.